CRISPR Knockout Validated Antibodies

Total Page:16

File Type:pdf, Size:1020Kb

Load more

CRISPR knockout validated antibodies Title Host Reactivity Catalog # Trial Size 10ugPrice € 5'-Nucleotidase, Ecto (NT5E) polyclonal antibody - Knockout Validated Rabbit Bovine, Human CDPAB05265-10 99 Acid Phosphatase 1 (ACP1) polyclonal antibody - Knockout Validated Rabbit Human, Rat CDPAB05701-10 99 Acidic Nuclear Phosphoprotein 32 Family, Member A (ANP32A) polyclonal antibody - KnockoutRabbit ValidatedHuman, Rat CDPAB00688-10 99 Actinin Alpha 2 (ACTN2) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB07017-10 99 Actinin Alpha 4 (ACTN4) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB03531-10 99 Activated Leukocyte Cell Adhesion Molecule (ALCAM) polyclonal antibody - Knockout ValidatedRabbit Human, Mouse, Rat CDPAB08037-10 99 Adducin 1 (ADD1) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB03462-10 99 Adhesion Regulating Molecule 1 (ADRM1) polyclonal antibody - Knockout Validated Rabbit Human CDPAB03459-10 99 Aldose Reductase Like Protein 1 (ARL1) polyclonal antibody - Knockout Validated Rabbit Human CDPAB00148-10 99 Alpha-Fetoprotein (aFP) polyclonal antibody - Knockout Validated Rabbit Human CDPAB07437-10 99 Alpha-Fetoprotein (aFP) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB07438-10 99 Aminoacylase 1 (ACY1) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB03467-10 99 Ancient Ubiquitous Protein 1 (AUP1) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB03427-10 99 Angiopoietin 2 (ANGPT2) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB08011-10 99 Annexin A1 (ANXA1) monoclonal Antibody - Knockout Validated Mouse Human, Mouse CDMAB00519-10 99 Annexin A3 (ANXA3) monoclonal Antibody - Knockout Validated Mouse Human CDMAB00307-10 99 Annexin A9 (ANXA9) polyclonal antibody - Knockout Validated Rabbit Human CDPAB01691-10 99 Anthrax Toxin Receptor 2 (ANTXR2) polyclonal antibody - Knockout Validated Rabbit Human, Pig, Rat CDPAB01573-10 99 Apoptosis Inducing Factor (AIF) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB05578-10 99 Aryl Hydrocarbon Receptor (AhR) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB05089-10 99 Asparagine Synthetase (ASNS) polyclonal antibody - Knockout Validated Rabbit Human CDPAB02116-10 99 Asparaginyl tRNA Synthetase (NARS) polyclonal antibody - Knockout Validated Rabbit Human CDPAB02685-10 99 Aspartyl tRNA Synthetase (DARS) polyclonal antibody - Knockout Validated Rabbit Human CDPAB02670-10 99 ATP Binding Cassette Transporter B8 (ABCB8) polyclonal antibody - Knockout Validated Rabbit Human CDPAB02213-10 99 ATP Binding Cassette Transporter D2 (ABCD2) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB02192-10 99 ATP Binding Cassette Transporter F1 (ABCF1) polyclonal antibody - Knockout Validated Rabbit Human CDPAB02203-10 99 ATPase, Na+/K+ Transporting Beta 3 Polypeptide (ATP1b3) polyclonal antibody - KnockoutRabbit ValidatedHuman, Rat CDPAB06291-10 99 Azurocidin 1 (AZU1) polyclonal antibody - Knockout Validated Rabbit Human, Rat CDPAB04893-10 99 B-Cell Leukemia/Lymphoma 2 (Bcl2) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB06172-10 99 B-Cell Leukemia/Lymphoma 2 (Bcl2) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB06173-10 99 Beclin 1 (BECN1) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB00701-10 99 BH3 Interacting Domain Death Agonist (Bid) polyclonal antibody - Knockout Validated Rabbit Human CDPAB06489-10 99 Biliverdin Reductase B (BLVRB) polyclonal antibody - Knockout Validated Rabbit Human, Rat CDPAB00706-10 99 Calcium Modulating Ligand (CAMLG) polyclonal antibody - Knockout Validated Rabbit Human, Mouse, Rat CDPAB03374-10 99 Calmodulin Like Protein 3 (CALML3) polyclonal antibody - Knockout Validated Rabbit Human, Rat CDPAB01362-10 99 Calmodulin Like Protein 5 (CALML5) polyclonal antibody - Knockout Validated Rabbit Human CDPAB01363-10 99 Calpain 9 (CAPN9) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB02717-10 99 Calumenin (CALU) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB04184-10 99 Canopy 2 Homolog (CNPY2) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB00302-10 99 Carcinoembryonic Antigen (CEA) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB07444-10 99 Caspase 1 (CASP1) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB04657-10 99 Caspase 1 (CASP1) polyclonal antibody - Knockout Validated Rabbit Human CDPAB04659-10 99 Caspase 2 (CASP2) polyclonal antibody - Knockout Validated Rabbit Human CDPAB08196-10 99 Caspase 3 (CASP3) polyclonal antibody - Knockout Validated Rabbit Human CDPAB06501-10 99 Caspase 8 (CASP8) polyclonal antibody - Knockout Validated Rabbit Human CDPAB05949-10 99 Caspase 8 (CASP8) polyclonal antibody - Knockout Validated Rabbit Human CDPAB05951-10 99 Caspase 9 (CASP9) polyclonal antibody - Knockout Validated Rabbit Human CDPAB06497-10 99 Caspase Recruitment Domain Family, Member 9 (CARD9) polyclonal antibody - KnockoutRabbit ValidatedHuman CDPAB00231-10 99 Catalase (CAT) polyclonal antibody - Knockout Validated Rabbit Human CDPAB03304-10 99 Cathepsin Z (CTSZ) polyclonal antibody - Knockout Validated Rabbit Human CDPAB02705-10 99 Centromere Protein H (CENPH) polyclonal antibody - Knockout Validated Rabbit Human CDPAB07230-10 99 Chaperonin Containing TCP1, Subunit 2 (CCT2) polyclonal antibody - Knockout ValidatedRabbit Human, Mouse CDPAB00493-10 99 Chordin Like Protein 1 (CHRDL1) polyclonal antibody - Knockout Validated Rabbit Human, Mouse, Rat CDPAB01434-10 99 Chromobox Homolog 3 (CBX3) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB03362-10 99 Cluster Of Differentiation 19 (CD19) polyclonal antibody - Knockout Validated Rabbit Mouse, Rat CDPAB04148-10 99 Cluster Of Differentiation 276 (CD276) polyclonal antibody - Knockout Validated Rabbit Human CDPAB06159-10 99 Coactosin Like Protein 1 (COTL1) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB00733-10 99 Collagen Type III Alpha 1 (COL3a1) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB02494-10 99 Complement Component 2 (C2) polyclonal antibody - Knockout Validated Rabbit Human CDPAB05922-10 99 Corticosteroid Binding Globulin (CBG) polyclonal antibody - Knockout Validated Rabbit Human CDPAB05324-10 99 Cyclin B (CCNB) polyclonal antibody - Knockout Validated Rabbit Human CDPAB02450-10 99 Cyclin D1 (CCND1) polyclonal antibody - Knockout Validated Rabbit Human, Mouse, rat CDPAB06592-10 99 Cyclin Dependent Kinase 18 (CDK18) polyclonal antibody - Knockout Validated Rabbit Human CDPAB01779-10 99 Cyclin Dependent Kinase 4 (CDK4) polyclonal antibody - Knockout Validated Rabbit Human, Rat CDPAB05301-10 99 Cyclophilin D (CYPD) polyclonal antibody - Knockout Validated Rabbit Human, Mouse, Rat CDPAB04762-10 99 Cyclophilin D (CYPD) polyclonal antibody - Knockout Validated Rabbit Human, Mouse, Rat CDPAB04764-10 99 Cystatin B (CSTB) polyclonal antibody - Knockout Validated Rabbit Human CDPAB00747-10 99 Cysteine And Glycine Rich Protein 1 (CSRP1) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB01539-10 99 Cytochrome P450 26A1 (CYP26A1) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB02284-10 99 Cytokeratin Fragment Antigen 21-1 (CYFRA21-1) polyclonal antibody - Knockout ValidatedRabbit Human CDPAB05272-10 99 Cytoplasmic Antiproteinase 3 (CAP3) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB02372-10 99 Deoxyribonuclease I (DNASE1) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB05470-10 99 Dihydrolipoyl Dehydrogenase (DLD) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB05830-10 99 Dipeptidyl Peptidase 3 (DPP3) polyclonal antibody - Knockout Validated Rabbit Human, Rat CDPAB02004-10 99 Discs, Large Homolog 5 (DLG5) polyclonal antibody - Knockout Validated Rabbit Human, Mouse CDPAB02616-10 99 Dopamine Beta Hydroxylase (DbH) polyclonal antibody - Knockout Validated Rabbit Human CDPAB04952-10 99 Dyskerin (DKC) polyclonal antibody - Knockout Validated Rabbit Human CDPAB03274-10 99 Early B-Cell Factor 1 (EBF1) polyclonal antibody - Knockout Validated Rabbit Human, Rat CDPAB04962-10 99 Early Growth Response Protein 2 (EGR2) polyclonal antibody - Knockout Validated Rabbit Human, Pig CDPAB04909-10 99 Enolase, Neuron Specific (NSE) polyclonal antibody - Knockout Validated Rabbit Human, mouse, Rat CDPAB06724-10 99 Enolase, Neuron Specific (NSE) polyclonal antibody - Knockout Validated Rabbit Human, Mouse, Rat CDPAB06725-10 99 Enolase, Neuron Specific (NSE) polyclonal antibody - Knockout Validated Rabbit Human, Mouse, Rat CDPAB06728-10 99 Enolase, Non Neuronal (NNE) polyclonal antibody - Knockout Validated Rabbit Human, mouse CDPAB04910-10 99 Ephrin Type A Receptor 10 (EPHA10) polyclonal antibody - Knockout Validated Rabbit Human, Rat CDPAB01921-10 99 Epithelial Stromal Interaction 1, Breast (EPSTI1) polyclonal antibody - Knockout ValidatedRabbit Human, Pig CDPAB01324-10 99 Eukaryotic Translation Elongation Factor 1 Alpha 1 (EEF1a1) polyclonal antibody - KnockoutRabbit ValidatedHuman, mouse CDPAB01600-10 99 Exportin 1 (XPO1) polyclonal antibody - Knockout Validated Rabbit Human, pig CDPAB03493-10 99 Fas Associating Death Domain Containing Protein (FADD) polyclonal antibody - KnockoutRabbit ValidatedHuman CDPAB00614-10 99 Fibrillarin (FBL) polyclonal antibody - Knockout Validated Rabbit Human, Rat CDPAB03214-10 99 Fibrinogen Beta (FGb) polyclonal antibody - Knockout Validated Rabbit Human CDPAB05344-10
Recommended publications
  • Keratin 19 Regulates Cell Shape and Cell-Cell Adhesion of MCF7 Cells While Maintaining E-Cadherin Localization at the Cell Surface

    Keratin 19 Regulates Cell Shape and Cell-Cell Adhesion of MCF7 Cells While Maintaining E-Cadherin Localization at the Cell Surface

    Keratin 19 regulates cell shape and cell-cell adhesion of MCF7 cells while maintaining E-cadherin localization at the cell surface Welcome to my poster. This is Sarah Alsharif, a PhD student from the biology department. I am glad to present the work our lab has been doing in the breast cancer field. In fact, after lung cancer, breast cancer is the second cause of death in women worldwide (1). It is estimated that every 18 seconds, approximately one new case of breast cancer is documented (2). No one dies due to cancer itself. The death is because of metastasis which takes place when cancer cells leave a breast in which they are formed and reach other sites such as the brain or lung. Our lab is interested in investigating the mechanism behind metastasis of breast cancer. Metastasis is associated with what is called epithelial to mesenchymal transition (EMT), the process characterized by loss of cell to cell adhesion and expression of epithelial markers such as keratin intermediate filament proteins, as you can see in the first three images of cells. Those filaments are keratins and they are critical for the shape and for maintaining mechanical integrity of epithelial cells via cell to cell complexes called desmosomes. Among different keratins, keratin 19 (K19) is highly expressed in many types of cancer including breast cancer, and is correlated with a worse prognosis (3). Consistently, K19 expression has been reported to be significantly higher in metastatic breast cancer tumor cells compared to primary tumors (4). The role of K19 on mechanical properties of cancer cells for cell migration and possible impact on metastasis in breast cancer patients is still unknown.
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas

    Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas

    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
  • Cytokine Nomenclature

    Cytokine Nomenclature

    RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B
  • A Cell Line P53 Mutation Type UM

    A Cell Line P53 Mutation Type UM

    A Cell line p53 mutation Type UM-SCC 1 wt UM-SCC5 Exon 5, 157 GTC --> TTC Missense mutation by transversion (Valine --> Phenylalanine UM-SCC6 wt UM-SCC9 wt UM-SCC11A wt UM-SCC11B Exon 7, 242 TGC --> TCC Missense mutation by transversion (Cysteine --> Serine) UM-SCC22A Exon 6, 220 TAT --> TGT Missense mutation by transition (Tyrosine --> Cysteine) UM-SCC22B Exon 6, 220 TAT --> TGT Missense mutation by transition (Tyrosine --> Cysteine) UM-SCC38 Exon 5, 132 AAG --> AAT Missense mutation by transversion (Lysine --> Asparagine) UM-SCC46 Exon 8, 278 CCT --> CGT Missense mutation by transversion (Proline --> Alanine) B 1 Supplementary Methods Cell Lines and Cell Culture A panel of ten established HNSCC cell lines from the University of Michigan series (UM-SCC) was obtained from Dr. T. E. Carey at the University of Michigan, Ann Arbor, MI. The UM-SCC cell lines were derived from eight patients with SCC of the upper aerodigestive tract (supplemental Table 1). Patient age at tumor diagnosis ranged from 37 to 72 years. The cell lines selected were obtained from patients with stage I-IV tumors, distributed among oral, pharyngeal and laryngeal sites. All the patients had aggressive disease, with early recurrence and death within two years of therapy. Cell lines established from single isolates of a patient specimen are designated by a numeric designation, and where isolates from two time points or anatomical sites were obtained, the designation includes an alphabetical suffix (i.e., "A" or "B"). The cell lines were maintained in Eagle's minimal essential media supplemented with 10% fetal bovine serum and penicillin/streptomycin.
  • Genetic Background Effects of Keratin 8 and 18 in a DDC-Induced Hepatotoxicity and Mallory-Denk Body Formation Mouse Model

    Genetic Background Effects of Keratin 8 and 18 in a DDC-Induced Hepatotoxicity and Mallory-Denk Body Formation Mouse Model

    Laboratory Investigation (2012) 92, 857–867 & 2012 USCAP, Inc All rights reserved 0023-6837/12 $32.00 Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model Johannes Haybaeck1, Cornelia Stumptner1, Andrea Thueringer1, Thomas Kolbe2, Thomas M Magin3, Michael Hesse4, Peter Fickert5, Oleksiy Tsybrovskyy1, Heimo Mu¨ller1, Michael Trauner5,6, Kurt Zatloukal1 and Helmut Denk1 Keratin 8 (K8) and keratin 18 (K18) form the major hepatocyte cytoskeleton. We investigated the impact of genetic loss of either K8 or K18 on liver homeostasis under toxic stress with the hypothesis that K8 and K18 exert different functions. krt8À/À and krt18À/À mice crossed into the same 129-ola genetic background were treated by acute and chronic ad- ministration of 3,5-diethoxy-carbonyl-1,4-dihydrocollidine (DDC). In acutely DDC-intoxicated mice, macrovesicular steatosis was more pronounced in krt8À/À and krt18À/À compared with wild-type (wt) animals. Mallory-Denk bodies (MDBs) appeared in krt18À/À mice already at an early stage of intoxication in contrast to krt8À/À mice that did not display MDB formation when fed with DDC. Keratin-deficient mice displayed significantly lower numbers of apoptotic hepatocytes than wt animals. krt8À/À, krt18À/À and control mice displayed comparable cell proliferation rates. Chronically DDC-intoxicated krt18À/À and wt mice showed a similarly increased degree of steatohepatitis with hepatocyte ballooning and MDB formation. In krt8À/À mice, steatosis was less, ballooning, and MDBs were absent. krt18À/À mice developed MDBs whereas krt8À/À mice on the same genetic background did not, highlighting the significance of different structural properties of keratins.
  • Oncostatin M Exhibit Elevated Responsiveness to IL-31 Receptor

    Oncostatin M Exhibit Elevated Responsiveness to IL-31 Receptor

    IL-31 Receptor (IL-31RA) Knockout Mice Exhibit Elevated Responsiveness to Oncostatin M This information is current as Janine Bilsborough, Sherri Mudri, Eric Chadwick, Brandon of September 28, 2021. Harder and Stacey R. Dillon J Immunol 2010; 185:6023-6030; Prepublished online 18 October 2010; doi: 10.4049/jimmunol.0902769 http://www.jimmunol.org/content/185/10/6023 Downloaded from References This article cites 29 articles, 6 of which you can access for free at: http://www.jimmunol.org/content/185/10/6023.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology IL-31 Receptor (IL-31RA) Knockout Mice Exhibit Elevated Responsiveness to Oncostatin M Janine Bilsborough,1 Sherri Mudri,1 Eric Chadwick,2 Brandon Harder,3 and Stacey R. Dillon IL-31 signals through the heterodimeric receptor IL-31RA and oncostatin M receptor (OSMR), and has been linked with the development of atopic dermatitis, a Th2 cytokine-associated disease in humans.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS

    Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS

    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
  • System, Method and Software for Calculation of a Cannabis Drug Efficiency Index for the Reduction of Inflammation

    System, Method and Software for Calculation of a Cannabis Drug Efficiency Index for the Reduction of Inflammation

    International Journal of Molecular Sciences Article System, Method and Software for Calculation of a Cannabis Drug Efficiency Index for the Reduction of Inflammation Nicolas Borisov 1,† , Yaroslav Ilnytskyy 2,3,†, Boseon Byeon 2,3,4,†, Olga Kovalchuk 2,3 and Igor Kovalchuk 2,3,* 1 Moscow Institute of Physics and Technology, 9 Institutsky lane, Dolgoprudny, Moscow Region 141701, Russia; [email protected] 2 Department of Biological Sciences, University of Lethbridge, Lethbridge, AB T1K 3M4, Canada; [email protected] (Y.I.); [email protected] (B.B.); [email protected] (O.K.) 3 Pathway Rx., 16 Sandstone Rd. S., Lethbridge, AB T1K 7X8, Canada 4 Biomedical and Health Informatics, Computer Science Department, State University of New York, 2 S Clinton St, Syracuse, NY 13202, USA * Correspondence: [email protected] † First three authors contributed equally to this research. Abstract: There are many varieties of Cannabis sativa that differ from each other by composition of cannabinoids, terpenes and other molecules. The medicinal properties of these cultivars are often very different, with some being more efficient than others. This report describes the development of a method and software for the analysis of the efficiency of various cannabis extracts to detect the anti-inflammatory properties of the various cannabis extracts. The method uses high-throughput gene expression profiling data but can potentially use other omics data as well. According to the signaling pathway topology, the gene expression profiles are convoluted into the signaling pathway activities using a signaling pathway impact analysis (SPIA) method. The method was tested by inducing inflammation in human 3D epithelial tissues, including intestine, oral and skin, and then exposing these tissues to various extracts and then performing transcriptome analysis.
  • Structural Heterogeneity of Cellular K5/K14 Filaments As Revealed by Cryo

    Structural Heterogeneity of Cellular K5/K14 Filaments As Revealed by Cryo

    bioRxiv preprint doi: https://doi.org/10.1101/2021.05.12.442145; this version posted May 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Structural heterogeneity of cellular K5/K14 filaments as revealed by cryo- 2 electron microscopy 3 4 Short title: Structural heterogeneity of keratin filaments 5 6 7 Miriam S. Weber1, Matthias Eibauer1, Suganya Sivagurunathan2, Thomas M. Magin3, Robert D. 8 Goldman2, Ohad Medalia1* 9 1Department of Biochemistry, University of Zurich, Switzerland 10 2Department of Cell and Developmental Biology, Northwestern University Feinberg School of 11 Medicine, USA 12 3Institute of Biology, University of Leipzig, Germany 13 14 * Corresponding author: [email protected] 15 16 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.05.12.442145; this version posted May 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 17 Abstract 18 Keratin intermediate filaments are an essential and major component of the cytoskeleton in epithelial 19 cells. They form a stable yet dynamic filamentous network extending from the nucleus to the cell 20 periphery. Keratin filaments provide cellular resistance to mechanical stresses, ensure cell and tissue 21 integrity in addition to regulatory functions. Mutations in keratin genes are related to a variety of 22 epithelial tissue diseases that mostly affect skin and hair. Despite their importance, the molecular 23 structure of keratin filaments remains largely unknown. In this study, we analyzed the structure of 24 keratin 5/keratin 14 filaments within ghost keratinocytes by cryo-electron microscopy and cryo- 25 electron tomography.
  • Quantigene Flowrna Probe Sets Currently Available

    Quantigene Flowrna Probe Sets Currently Available

    QuantiGene FlowRNA Probe Sets Currently Available Accession No. Species Symbol Gene Name Catalog No. NM_003452 Human ZNF189 zinc finger protein 189 VA1-10009 NM_000057 Human BLM Bloom syndrome VA1-10010 NM_005269 Human GLI glioma-associated oncogene homolog (zinc finger protein) VA1-10011 NM_002614 Human PDZK1 PDZ domain containing 1 VA1-10015 NM_003225 Human TFF1 Trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) VA1-10016 NM_002276 Human KRT19 keratin 19 VA1-10022 NM_002659 Human PLAUR plasminogen activator, urokinase receptor VA1-10025 NM_017669 Human ERCC6L excision repair cross-complementing rodent repair deficiency, complementation group 6-like VA1-10029 NM_017699 Human SIDT1 SID1 transmembrane family, member 1 VA1-10032 NM_000077 Human CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) VA1-10040 NM_003150 Human STAT3 signal transducer and activator of transcripton 3 (acute-phase response factor) VA1-10046 NM_004707 Human ATG12 ATG12 autophagy related 12 homolog (S. cerevisiae) VA1-10047 NM_000737 Human CGB chorionic gonadotropin, beta polypeptide VA1-10048 NM_001017420 Human ESCO2 establishment of cohesion 1 homolog 2 (S. cerevisiae) VA1-10050 NM_197978 Human HEMGN hemogen VA1-10051 NM_001738 Human CA1 Carbonic anhydrase I VA1-10052 NM_000184 Human HBG2 Hemoglobin, gamma G VA1-10053 NM_005330 Human HBE1 Hemoglobin, epsilon 1 VA1-10054 NR_003367 Human PVT1 Pvt1 oncogene homolog (mouse) VA1-10061 NM_000454 Human SOD1 Superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))
  • P63 Transcription Factor Regulates Nuclear Shape and Expression of Nuclear Envelope

    P63 Transcription Factor Regulates Nuclear Shape and Expression of Nuclear Envelope

    Durham Research Online Deposited in DRO: 21 September 2017 Version of attached le: Published Version Peer-review status of attached le: Peer-reviewed Citation for published item: Rapisarda, Valentina and Malashchuk, Igor and Asamaowei, Inemo E. and Poterlowicz, Krzysztof and Fessing, Michael Y. and Sharov, Andrey A. and Karakesisoglou, Iakowos and Botchkarev, Vladimir A. and Mardaryev, Andrei (2017) 'p63 transcription factor regulates nuclear shape and expression of nuclear envelope-associated genes in epidermal keratinocytes.', Journal of investigative dermatology., 137 (10). pp. 2157-2167. Further information on publisher's website: https://doi.org/10.1016/j.jid.2017.05.013 Publisher's copyright statement: This article is available under the terms of the Creative Commons Attribution License (CC BY). You may copy and distribute the article, create extracts, abstracts and new works from the article, alter and revise the article, text or data mine the article and otherwise reuse the article commercially (including reuse and/or resale of the article) without permission from Elsevier. You must give appropriate credit to the original work, together with a link to the formal publication through the relevant DOI and a link to the Creative Commons user license above. You must indicate if any changes are made but not in any way that suggests the licensor endorses you or your use of the work. Additional information: Use policy The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that: • a full bibliographic reference is made to the original source • a link is made to the metadata record in DRO • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders.